通心络在缺血性卒中二级预防中的临床对照研究

A Cases-control Study of Tongxinluo in Secodary Prevention of Ischemic Stroke

目的:研究口服通心络在缺血性卒中二级预防中的作用。方法:缺血性卒中患者102例,在急性期治疗后分为通心络组和对照组,全部患者均进行TOAST分类及Rankin评分,随访6个月后的心脑血管事件发生率和神经功能恢复情况。结果:102例患者中,大动脉粥样硬化性血栓占23.5%,心源性脑栓塞占11.8%,小动脉病变占45%,其他原因占10.7%,未能确定病因占6.8%。6个月后通心络组与对照组的心脑血管事件发生率比较无统计学差异(P>0.05);据Rankin评分,治疗后全部患者均有神经功能改善。其中通心络组中小动脉病变患者治疗后与治疗前比较其神经功能显著改善(P<0.01),与对照组治疗后比较有显著差异(P<0.01)。结论:通心络是一种有效的缺血性卒中二级预防药物。

Objective：To assess whether Tongxinluo paid a role in the reduction of recurrent ischemic stroke. Methods： 102 hospital-admitted patients with acute ischemie stroke were divided into Tongxinluo treated group and control group. All these patients were classified according to TOAST ischemic stroke subtype and evaluated for neurological function （ Rankin scale）. The follow-up of 6 months was made to reassesses cerehral-cardial, Vascular events and Rankin scale. Results： The diagnoses of TOAST subtype in these patients were： undetermined 6.8% of patients ,large-artery atherosclerosis 23.5% ,cardioembolism 11.8% ,small artery disease 45%, and other specific etiologies 10.7%. There were no differences of new cerehral-cardial Vascular events between Tongxinluo treated（ n = 4 ） and controls（ n = 3 ） （ P 〉 0.05 ）. The Neurological function status （ Rankin scale ） in all patients were improved after 6 months. However,the statistical significance of better functional statues was only found in patients with small artery disease and treated by Tongxiuluo （P 〈 0.01 ）. Conclusion： Tongxinluo is effective in secondary prevention of isebemic stroke.